KURA ONCOLOGY, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
KURA ONCOLOGY, INC. (KURA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 21.67 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- KURA ONCOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 21.55M shares, a 20.58% increase year-over-year.
- KURA ONCOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 17.88M shares, a 19.95% increase year-over-year.
- KURA ONCOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 14.90M shares, a 32.06% increase year-over-year.
- KURA ONCOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 11.28M shares, a 18.77% increase year-over-year.
- KURA ONCOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 18.18M shares, a 17.82% increase from fiscal 2024.
- KURA ONCOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 15.43M shares, a 22.05% increase from fiscal 2023.
- KURA ONCOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 12.64M shares, a 36.43% increase from fiscal 2022.
- KURA ONCOLOGY, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 9.27M shares, a 29.49% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 21.67M shares 10-Q · filed 2026-08-12 | ||||||
| 2026-03-31 | 21.55M shares 10-Q · filed 2026-05-12 | ||||||
| 2025-12-31 | 18.18M shares 10-K · filed 2026-03-05 | ||||||
| 2025-09-30 | 18.56M shares 10-Q · filed 2025-11-04 | ||||||
| 2025-06-30 | 18.21M shares 10-Q · filed 2026-08-12 | ||||||
| 2025-03-31 | 17.88M shares 10-Q · filed 2026-05-12 | ||||||
| 2024-12-31 | 15.43M shares 10-K · filed 2026-03-05 | ||||||
| 2024-09-30 | 15.14M shares 10-Q · filed 2025-11-04 | ||||||
| 2024-06-30 | 15.09M shares 10-Q · filed 2025-08-07 | ||||||
| 2024-03-31 | 14.90M shares 10-Q · filed 2025-05-01 | ||||||
| 2023-12-31 | 12.64M shares 10-K · filed 2026-03-05 | ||||||
| 2023-09-30 | 12.66M shares 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | 13.74M shares 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | 11.28M shares 10-Q · filed 2024-05-02 | ||||||
| 2022-12-31 | 9.27M shares 10-K · filed 2025-02-28 | ||||||
| 2022-09-30 | 9.11M shares 10-Q · filed 2023-11-02 | ||||||
| 2022-06-30 | 9.10M shares 10-Q · filed 2023-08-09 | ||||||
| 2022-03-31 | 9.50M shares 10-Q · filed 2023-05-10 | ||||||
| 2021-12-31 | 7.16M shares 10-K · filed 2024-02-27 | ||||||
| 2021-09-30 | 6.95M shares 10-Q · filed 2021-11-04 | 6.95M shares 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | 7.00M shares 10-Q · filed 2021-08-05 | 7.00M shares 10-Q · filed 2022-08-03 | |||||
| 2021-03-31 | 6.83M shares 10-Q · filed 2022-05-04 | ||||||
| 2020-12-31 | 5.06M shares 10-K · filed 2023-02-23 | ||||||
| 2020-09-30 | 5.18M shares 10-Q · filed 2021-11-04 | 5.18M shares 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | 5.14M shares 10-Q · filed 2021-08-05 | 5.14M shares 10-Q · filed 2021-08-05 | |||||
| 2020-03-31 | 5.37M shares 10-Q · filed 2021-05-06 | ||||||
| 2019-12-31 | 4.12M shares 10-K · filed 2022-02-24 | ||||||
| 2019-09-30 | 4.10M shares 10-Q · filed 2020-11-05 | 4.10M shares 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | 4.14M shares 10-Q · filed 2020-08-06 | 4.14M shares 10-Q · filed 2020-08-06 | |||||
| 2019-03-31 | 4.38M shares 10-Q · filed 2020-05-04 | ||||||
| 2018-12-31 | 3.23M shares 10-K · filed 2021-02-24 | ||||||
| 2018-09-30 | 3.34M shares 10-Q · filed 2019-11-05 | 3.34M shares 10-Q · filed 2019-11-05 | |||||
| 2018-06-30 | 3.33M shares 10-Q · filed 2018-08-06 | 3.33M shares 10-Q · filed 2019-08-01 | |||||
| 2018-03-31 | 3.54M shares 10-Q · filed 2019-05-07 | ||||||
| 2017-12-31 | 3.06M shares 10-K · filed 2020-02-25 | ||||||
| 2017-09-30 | 3.30M shares 10-Q · filed 2018-11-05 | 3.30M shares 10-Q · filed 2018-11-05 | |||||
| 2017-06-30 | 3.63M shares 10-Q · filed 2018-08-06 | 3.64M shares 10-Q · filed 2017-08-07 | 3.63M shares 10-Q · filed 2018-08-06 | 3.64M shares 10-Q · filed 2017-08-07 | |||
| 2017-03-31 | 3.89M shares 10-Q · filed 2018-05-08 | 3.89M shares 10-Q · filed 2017-05-15 | |||||
| 2016-12-31 | 3.29M shares 10-K · filed 2018-03-12 | 3.29M shares 10-K · filed 2017-03-14 | |||||
| 2016-09-30 | 3.57M shares 10-Q · filed 2017-11-07 | 3.57M shares 10-Q · filed 2017-11-07 | |||||
| 2016-06-30 | 3.87M shares 10-Q · filed 2017-08-07 | 3.87M shares 10-Q · filed 2017-08-07 | |||||
| 2016-03-31 | 4.12M shares 10-Q · filed 2017-05-15 | ||||||
| 2015-12-31 | 3.81M shares 10-K · filed 2017-03-14 | ||||||
| 2015-03-31 | 4.19M shares 10-Q · filed 2015-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |